EP
CRSP icon

Eversept Partners’s CRISPR Therapeutics CRSP Stock Holding History

Eversept Partners’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-42,400
Closed -$1.51M – 64
2019
Q1 		$1.51M Buy
+42,400
New +$1.47M 0.44% 35

Other funds holding CRSP

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Eversept Partners's CRSP Position: Q2 2019 in Review

Eversept Partners sold out of CRISPR Therapeutics (CRSP) in Q2 2019, closing a stake of 42,400 shares — an estimated $1.51M sold.

Eversept Partners first reported a position in CRSP in Q1 2019 and held it in 1 quarter. The position peaked at $1.51M in Q1 2019. 181 funds tracked by Wall St. Rank hold CRSP as of Q2 2019.

  • Eversept Partners reported no remaining CRISPR Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Eversept Partners sold 42,400 CRISPR Therapeutics shares in Q2 2019, an estimated $1.51M.
  • Eversept Partners first reported a position in CRISPR Therapeutics in Q1 2019 and held it in 1 quarter.
  • Eversept Partners's CRISPR Therapeutics position peaked at $1.51M in Q1 2019.
  • 181 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2019.

Based on Eversept Partners's 13F filing for Q2 2019, filed 13 Aug 2019.